Avastin (bevacizumab) is a prescription drug used to treat certain types of cancer. Avastin is also available as a biosimilar drug. It’s prescribed for adults ages 18 years and older.

Amgen and Allergan’s biosimilar of Roche’s cancer blockbuster Avastin has been approved in the EU, but there could be a four-year wait before the drug makes it to the market. The patent ...

marketed as Tecentriq and Avastin by Roche (OTCQX:RHHBY) (OTCQX:RHHBF). The global Phase 1b/2 study tested amezalpat in combination with atezolizumab and bevacizumab against the standard of care ...

The Phase II trial will compare the efficacy and safety of the Hepazo kit when used in combination with the standard of care, ...

Amgen and Allergan's biosimilar of Roche’s cancer drug Avastin is on the cusp of approval in Europe, but a launch could be years away because of patent protection. While the US patent on Avastin ...